BeOne Medicines Ltd
ONCHealthcare|Biotechnology|Switzerland
$298.70
-4.13 (-1.36%)
Tangible Book
$42.27
Graham Number
$97.57
Upcoming Data Readouts (65)
Jul 2026
Est. completion
P3Gastric Neoplasms
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147n=920
Aug 2026
Est. completion
P1Breast Cancer
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264n=103
Aug 2026
Est. completion
P1Mature B-cell Malignancies
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
NCT04883957n=64
Sep 2026
Est. completion
P2Waldenstrom Macroglobulinemia
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037n=114
Sep 2026
Est. completion
P1Healthy Volunteers
A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults
NCT07628881n=12
Sep 2026
Est. completion
P1Healthy Volunteers
A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants
NCT07590102n=30
Nov 2026
Est. completion
P1P2Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605n=246
Nov 2026
Est. completion
P2MSI-H/dMMR Solid Tumors
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
NCT03736889n=200
Nov 2026
Est. completion
P1P2B-cell Malignancy
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716n=645
Nov 2026
Est. completion
P2Chronic Lymphocytic Leukemia
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501n=94
Dec 2026
Est. completion
Waldenstrom Macroglobulinemia
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
NCT05640102n=111
Dec 2026
Est. completion
P2Waldenstrom Macroglobulinemia
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
NCT06561347n=56
Dec 2026
Est. completion
P2Recurrent Transformed Chronic Lymphocytic Leukemia
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
NCT05873712n=24
Dec 2026
Est. completion
P1Advanced Solid Tumor
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593n=168
Feb 2027
Est. completion
P2Chronic Lymphocytic Leukemia (CLL)
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
NCT03824483n=230
Mar 2027
Est. completion
P3Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297n=510
Apr 2027
Est. completion
P1Extensive Stage Small Cell Lung Cancer
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
NCT06598306n=220
May 2027
Est. completion
P1Mature B-Cell Malignancies
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
NCT04277637n=437
Jun 2027
Est. completion
P3Urothelial Carcinoma
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977n=420
Jul 2027
Est. completion
P1Hormone-receptor-positive Breast Cancer
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932n=120
Awaiting Results (8)
Trials past primary completion date but still active — data readout may be imminent.
Dec 2025
P2
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT05635708Dec 2025
P3
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
NCT03519230May 2025
P1P2
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
NCT05661955May 2025
P1P2
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370Jan 2025
P2
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Aug 2023
P3
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
NCT04379635May 2021
P3
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333